Loading...
OTC Markets
Totals
Securities
12,214
Dollar Vol
$2.7B
Share Vol
3.1B
Trades
358,241

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

SPHRY
Starpharma Holdings Ltd.

Sponsored ADR (1 ADS : 10 Ordinary)
Starpharma Holdings Ltd. Company Logo

4-6 Southampton Crescent

Abbotsford, VA 3067

Australia

Principal Executive Offices:

4-6 Southampton Crescent

Abbotsford, VIC 3067

Australia

Business Description
Starpharma Holdings Limited (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.
Financial Reporting
Reporting Status
International Reporting: ASX - Australian Securities Exchange
Audited Financials
Audited
CIK
0001308380
Fiscal Year End
6/30
Company Officers & Contacts
Cherly Maley
CEO

Justin Cahill
CFO, Company Secretary Manager

Andrew William Bond
Chief Accounting Officer

Board of Directors
Robert Thomas
Chairman, Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Russell Basser
Non-Executive Director, Independent Director, Compensation Committee Member, Nominating Committee Member

Lynda Cheng
Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Jeff Davies
Independent Director, Compensation Committee Member, Nominating Committee Member

David McIntyre
Independent Director, Audit Committee Member

Other Company Insiders

None

Other Company Insiders are all persons or entities beneficially owning 10% or more of any class of the issuer's securities. Together, officers, directors and other company insiders comprise Company Insiders.
Service Providers
Accounting/Auditing Firm
PricewaterhouseCoopers LLP

Level 19 Freshwater Place

2 Southbank Boulevard

Southbank, VA 3006

Australia

Securities Counsel
DLA Piper Australia

Level 31

152-158 St Georges Terrace

Perth, WA 6000

Australia

Securities Counsel
Rimon Law

Level 10, 20 Martin Place

Sydney, NSW 2000

Australia

Profile Data
SIC - Industry Classification
8731 - Commercial physical research
Incorporation Information
VA, AU, 1997
Employees
40 as of 12/03/2024
Shell
No
Products and Services

Starpharma has developed an innovative drug delivery platform using proprietary dendrimer nanoparticles, known as DEP®, to enhance the efficacy and tolerability of pharmaceutical products. Starpharma utilizes the DEP® technology for its own pipeline of assets and collaborates with partners to apply this technology to their drug discovery programs and pipeline assets. Starpharma’s portfolio of dendrimer-based products includes clinical-stage oncology assets, preclinical radiopharmaceuticals and antibody-drug conjugate (ADC) assets, research collaborations, and commercially marketed over-the-counter (OTC) products.

Company Facilities

Starpharma's HQ & facilities are located in Melbourne Australia.

Company Notes
Sponsored for OTCQX by BNY Mellon on 3/26/2007.
Formerly=Starpharma Pooled Development Ltd. until 4-04
OTCQX Best Market Logo
Joined OTCQX 03/2007
Securities
Other Starpharma Holdings Ltd. Securities
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.